Phase II Study of BEvacizumab (Avastin) in Combination With Atezolizumab or Atezolizumab (Tencentriq) and Cobimetinib (Cotellic) in Patients With Untreated Melanoma Brain Metastases (TACo-BEAT-MBM)
Latest Information Update: 21 May 2024
At a glance
- Drugs Atezolizumab (Primary) ; Bevacizumab (Primary) ; Cobimetinib (Primary)
- Indications Brain metastases; Malignant melanoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms TACo-BEAT-MBM
- 16 May 2024 Planned End Date changed from 30 Jun 2024 to 30 Jun 2026.
- 16 May 2024 Planned primary completion date changed from 30 Jun 2024 to 30 Jun 2026.
- 24 Oct 2023 Results presented at the 48th European Society for Medical Oncology Congress